Sign in

CIK 0001740279

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

IN8BIO, INC.

Sign in to watch
Ticker
INAB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
825462585
Phone
+1 646-600-6438
Business address
EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
Former names
Incysus Therapeutics, Inc.
  1. 4 Grant or award President and CEO acquired 81,967 shares (grant or award)
  2. 4 Grant or award Chief Financial Officer acquired 20,492 shares (grant or award)
  3. 4 Grant or award Chief Operating Officer acquired 12,295 shares (grant or award)
  4. 4 Grant or award Chief Medical Officer acquired 4,098 shares (grant or award)
  5. 4 Grant or award EVP and CSO acquired 1,639 shares (grant or award)
  6. 4 Grant or award Director acquired 81,967 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 4 Open-market buy Director bought 2,500 shares at $0.95 ($2,375)
  13. 4 Open-market buy Chief Financial Officer bought 1,000 shares at $1.03 ($1,030)
  14. 4 Open-market buy President and CEO bought 23,800 shares at $1.05 ($24,990)
  15. 4 Other disposition Director disposed of 4,111,958 shares (other)
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 5 of 10 · 185 filings